Relay Therapeutics Inc (RLAY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Relay Therapeutics Inc stock (RLAY) is currently trading at $9.44. Relay Therapeutics Inc PS ratio (Price-to-Sales) is 115.35. Analyst consensus price target for RLAY is $16.64. WallStSmart rates RLAY as Sell.
- RLAY PE ratio analysis and historical PE chart
- RLAY PS ratio (Price-to-Sales) history and trend
- RLAY intrinsic value — DCF, Graham Number, EPV models
- RLAY stock price prediction 2025 2026 2027 2028 2029 2030
- RLAY fair value vs current price
- RLAY insider transactions and insider buying
- Is RLAY undervalued or overvalued?
- Relay Therapeutics Inc financial analysis — revenue, earnings, cash flow
- RLAY Piotroski F-Score and Altman Z-Score
- RLAY analyst price target and Smart Rating
Relay Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Relay Therapeutics Inc (RLAY) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Relay Therapeutics Inc (RLAY) Key Strengths (1)
102.61% of shares held by major funds and institutions
Supporting Valuation Data
Relay Therapeutics Inc (RLAY) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -23.30%, a shrinking business
Very expensive at 115.3x annual revenue
Premium pricing at 3.1x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Relay Therapeutics Inc (RLAY) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (115.35), Price/Book (3.12) suggest expensive pricing. Growth concerns include Revenue Growth at -23.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -41.10%, Operating Margin at -899.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -41.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -23.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RLAY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RLAY's Price-to-Sales ratio of 115.35x sits near its historical average of 116.9x (17th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 4% below its historical high of 120.59x set in Mar 2026, and 3% above its historical low of 112.21x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Relay Therapeutics Inc (RLAY) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Relay Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 15M with 23% decline year-over-year.
Key Findings
Debt-to-equity ratio of 0.05 indicates a conservative balance sheet with 92M in cash.
Spending 361% of revenue (55M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 23% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -45M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.62, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Relay Therapeutics Inc.
Bottom Line
Relay Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(14 last 3 months)
| Insider | Type | Shares |
|---|---|---|
CATINAZZO, THOMAS Chief Financial Officer | Sell | -17,717 |
| Insider | Type | Shares |
|---|---|---|
PATEL, SANJIV Director, President and CEO | Sell | -43,168 |
Data sourced from SEC Form 4 filings
Last updated: 10:04:32 AM
About Relay Therapeutics Inc(RLAY)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Relay Therapeutics, Inc. is a clinical-stage precision drug company. The company is headquartered in Cambridge, Massachusetts.